Daclatasvir combo gets Breakthrough status

Share this article:

Bristol-Myers Squibb landed a Breakthrough Therapy designation for its daclatasvir + asunaprevir combination to treat genotype 1b hep. C. The regulator granted the designation based on Phase-III clinical data involving the all-oral, two-drug regimen.

If the drug mix sounds familiar, it is: the FDA granted Breakthrough Therapy status in October 2013 to an all-oral combination of daclatasvir, asunaprevir and BMS-791325, which is being studied in non-cirrhotic, treatment-naïve and experienced patients, as well as cirrhotic, treatment naïve and experienced patients.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.